[Treatment of acute group A beta-hemolytic streptococcal tonsillitis in children with a 5-day course of josamycin]. 2001

H Portier, and A Bourrillon, and F Lucht, and P Choutet, and P Géhanno, and L Meziane, and E Bingen, and
Service des maladies infectieuses et tropicales, centre hospitalier Bocage, 10, boulevard du Maréchal-de-Lattre-de-Tassigny, BP 1542, 21034 Dijon, France. henri.portier@chu-dijon.fr

METHODS In this randomized open study, 325 children aged two to 15 years with acute tonsillitis and a positive test of GA beta H streptococcal antigen were treated with josamycin 50 mg.kg-1.day-1 b.i.d for 5 days, or penicillin 50,000 to 100,000 IU/day t.i.d for 10 days. Clinical assessments and throat cultures for GA beta HS isolation were performed at the inclusion visit (V1), at the end of treatment visit (V2: day 12 for all patients) and at the follow-up visit (V3: day 30). In case of positive GA beta HS culture, the bacterial DNA by RFLP was performed to differentiate between the persistence (presence of original strain at V2), relapse (eradication at V2 and acquisition of same strain at V3) and reinfection (eradication at V2 and acquisition of different strain at V3). RESULTS Two hundred and twenty-three patients were included in the bacteriological and clinical criteria per protocol analysis. At V2, eradication rates were comparable: 82% in josamycin and 80% in penicillin patients; clinical cure rates were 90% and 89%. At V3, relapse of GAS assessed only on clinically and bacteriologically cured patients at V2 occurred in 12% of josamycin patients and 12.8% of penicillin patients. Tolerance was good; 14% and 10% of josamycin and penicillin patients respectively experienced an adverse event. CONCLUSIONS In this non-inferiority study, the efficacy of a 5-day course of josamycin is comparable to reference treatment in GA beta HS tonsillitis in children.

UI MeSH Term Description Entries
D007223 Infant A child between 1 and 23 months of age. Infants
D008297 Male Males
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D004352 Drug Resistance, Microbial The ability of microorganisms, especially bacteria, to resist or to become tolerant to chemotherapeutic agents, antimicrobial agents, or antibiotics. This resistance may be acquired through gene mutation or foreign DNA in transmissible plasmids (R FACTORS). Antibiotic Resistance,Antibiotic Resistance, Microbial,Antimicrobial Resistance, Drug,Antimicrobial Drug Resistance,Antimicrobial Drug Resistances,Antimicrobial Resistances, Drug,Drug Antimicrobial Resistance,Drug Antimicrobial Resistances,Drug Resistances, Microbial,Resistance, Antibiotic,Resistance, Drug Antimicrobial,Resistances, Drug Antimicrobial
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000208 Acute Disease Disease having a short and relatively severe course. Acute Diseases,Disease, Acute,Diseases, Acute
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths

Related Publications

H Portier, and A Bourrillon, and F Lucht, and P Choutet, and P Géhanno, and L Meziane, and E Bingen, and
July 2017, International archives of otorhinolaryngology,
H Portier, and A Bourrillon, and F Lucht, and P Choutet, and P Géhanno, and L Meziane, and E Bingen, and
October 1994, The Annals of pharmacotherapy,
H Portier, and A Bourrillon, and F Lucht, and P Choutet, and P Géhanno, and L Meziane, and E Bingen, and
May 1999, Archives of otolaryngology--head & neck surgery,
H Portier, and A Bourrillon, and F Lucht, and P Choutet, and P Géhanno, and L Meziane, and E Bingen, and
November 1969, Nihon Densenbyo Gakkai zasshi,
H Portier, and A Bourrillon, and F Lucht, and P Choutet, and P Géhanno, and L Meziane, and E Bingen, and
August 1994, Israel journal of medical sciences,
H Portier, and A Bourrillon, and F Lucht, and P Choutet, and P Géhanno, and L Meziane, and E Bingen, and
November 1998, European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology,
H Portier, and A Bourrillon, and F Lucht, and P Choutet, and P Géhanno, and L Meziane, and E Bingen, and
January 2004, Advances in therapy,
H Portier, and A Bourrillon, and F Lucht, and P Choutet, and P Géhanno, and L Meziane, and E Bingen, and
July 2003, Pediatrics,
H Portier, and A Bourrillon, and F Lucht, and P Choutet, and P Géhanno, and L Meziane, and E Bingen, and
November 1987, The Pediatric infectious disease journal,
H Portier, and A Bourrillon, and F Lucht, and P Choutet, and P Géhanno, and L Meziane, and E Bingen, and
April 1992, Pediatrics,
Copied contents to your clipboard!